Information Provided By:
Fly News Breaks for December 23, 2015
ONTY
Dec 23, 2015 | 06:21 EDT
Jefferies analyst Gena Wang assumed coverage of Oncothyreon with a Buy rating and $4 price target. The analyst previously had a Buy rating and $5 price target on the name. The company's lead candidate ONT-380 demonstrated initial clinical activity from two Phase 1 trials in HER2+ metastatic breast cancer, Wang tells investors.
News For ONTY From the Last 2 Days
There are no results for your query ONTY